GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
You may also be interested in...
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Genelabs, Taiwan National Health Research Institutes and Genovate To Co-Develop New Hepatitis C Treatment
SHANGHAI - Genelabs Technologies inked a development agreement with the Taiwan National Health Research Institutes and Genovate Biotechnology to co-develop drugs to treat hepatitis C, the company announced July 23
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.